The effect of serotonin receptor blocking agents--cyproheptadine and danitracen--on serotonin turnover in the rat brain. 1977

K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj

Cyproheptadine (CPH), 0.5 mg/kg ip, did not affect the cerebral serotonin (5-HT) level, but elevated the level of 5-hydroxyindoleacetic acid (5-HIAA). Danitracen (DN), 1 mg/kg ip, depressed the cerebral 5-HT level and elevated the 5-HIAA level, but at a dose 10 mg/kg did not affect the levels of either the amine, or its metabolite. Both CPH and DN, 1 mg/kg, significantly potentiated the disappearance of 5-HT after administration of p-chlorophenylalanine. DN, in a low dose, accelerated the disappearance of 5-HT after inhibition of 5-HT synthesis by alpha-propyldopacetamide. The rate of accumulation of 5-HIAA after probenecid, was increased only by CPH. CPH did not affect the 5-HT accumulation after pargyline, while DN depressed its accumulation. The results of experiments on the levels of 5-HT and 5-HIAA, and on the rate of disappearance of 5-HT after inhibition of tryptophan decarboxylase suggest that CPH and DN increase the 5-HT turnover. The results of studies on the turnover rate of 5-HT after administration of probenecid and parygline do not corroborate fully this assumption. Possibly, this discrepancy may depend on differences in the action of 5-HT in various brain areas and interaction of serotoninolytics tested with effects of the MAO inhibitor.

UI MeSH Term Description Entries
D008297 Male Males
D010134 Fenclonine A selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin. p-Chlorophenylalanine,para-Chlorophenylalanine,CP-10,188,DL-3-(4-Chlorophenyl)alanine,Fenclonin,Fenclonine (L)-Isomer,Fenclonine Hydrobromide,Fenclonine Hydrochloride,Fenclonine, (D)-Isomer,Hydrobromide, Fenclonine,Hydrochloride, Fenclonine,para Chlorophenylalanine
D010293 Pargyline A monoamine oxidase inhibitor with antihypertensive properties. Pargyline Hydrochloride,Hydrochloride, Pargyline
D010880 Piperidines A family of hexahydropyridines.
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003533 Cyproheptadine A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. Antergan,Dihexazin,Periactin,Peritol,Viternum
D006897 Hydroxyindoleacetic Acid 5-HIAA,5-Hydroxy-3-Indoleacetic Acid,5-Hydroxyindolamine Acetic Acid,5 Hydroxy 3 Indoleacetic Acid,5 Hydroxyindolamine Acetic Acid,Acetic Acid, 5-Hydroxyindolamine,Acid, 5-Hydroxy-3-Indoleacetic,Acid, 5-Hydroxyindolamine Acetic,Acid, Hydroxyindoleacetic
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
January 1976, Polish journal of pharmacology and pharmacy,
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
January 1993, Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina,
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
December 1974, European journal of pharmacology,
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
June 1974, Psychopharmacologia,
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
February 1978, Pharmacological research communications,
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
July 1975, Life sciences,
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
December 1979, Brain research,
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
December 2002, Lancet (London, England),
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
September 1972, Biochemical pharmacology,
K Golembiowska-Nikitin, and G Wiszniowska, and J Marchaj
August 1977, Research communications in chemical pathology and pharmacology,
Copied contents to your clipboard!